A major international company chose Arrow Medical to manufacture a high volume garment used for prophylaxis treatment of deep vein thrombosis (DVT). This required specialist cutting and sewing operations that are now well established and highly productive parts of Arrow Medical’s capability. Arrow Medical’s commitment to quality continued with the further investment when the company diversified into injection and compression moulding for both silicone and organic elastomers.
Arrow Single And Double Lumen Hemodialysis Catheter kit
Center Venus Catheter
Pressure Injectable CVCs
Many patients who receive a Central Venous Catheter will require a CT scan. To streamline patient care, our ARROW® CVCs are now available with pressure injection capabilities; up to 10 mL/sec of contrast for CT scanning.
If a central line is not rated for pressure-injectable contrast, the patient and clinician will need to wait for a second pressure injectable vascular access device to be placed. If a Pressure Injectable ARROW® CVC is in place, the patient can be sent for CT scanning immediately. An added advantage for CT techs is that ARROW® CVCs are larger than most PICCs, you can get faster flow rates of the injected contrast.
ARROWg+ard® Technology is a chlorhexidine-based technology impregnated into the catheter surface. Chlorhexidine/silver sulfadiazine antimicrobial catheters such as ARROW® CVCs with ARROWg+ard® Technology are a CDC 1A recommendation for the prevention of catheter-related bloodstream infection. The use of ARROWg+ard® Technology can protect against infections and therefore reduces costs by reducing infection. More than 30 studies2 verify the efficacy of the ARROWg+ard® Technology against a broad-spectrum of microbial activity. The ARROW® Brand catheter with ARROWg+ard® Technology has a strong track record.
- ARROWg+ard® Blue Technology is the 1st generation of the chlorhexidine-based antiseptic catheter. It is protected only on the outside of the catheter. ARROWg+ard Blue PLUS® Technology is protected with chlorhexidine-based technology on both the outside and inside of the catheter, the entire fluid pathway including the inside of the extension lines and hubs.
- Maki et al. found ARROWg+ard® Technology reduces bacterial colonization of the catheter by 44 percent and catheter-related bacteremia by an even greater 79 percent.3
- ARROWg+ard® Technology has been shown to be effective against the pathogens responsible for CLABSI (see chart below). This includes a wide array of gram-positive bacteria, including S. epidermidis, MRSA and S. aureus; gram-negative bacteria, including Enterococci and Pseudomonas strains; and fungi, including C. albicans.6
Protection Against the Causes of CLABSI
% OF ALL CLABSI
PROVEN EFFECTIVE IN VITRO6*
*Studies were done using ARROWg+ard Blue PLUS® Technology using In Vitro zone of inhibition test. ARROWg+ard Blue PLUS® Technology showed a minimum of a 4 mm zone of inhibition at day seven.